Cargando…
The journey of omega-3 fatty acids in cardiovascular medicine
In subjects with cardiovascular risk factors or in patients in need of secondary prevention, hypertriglyceridemia is a well-defined risk factor for adverse cardiac events. Drugs containing n-3 polyunsaturated fatty acids (n-3 PUFAs) are approved for treatment of hypertriglyceridemia. In 1999, a card...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537797/ https://www.ncbi.nlm.nih.gov/pubmed/33061867 http://dx.doi.org/10.1093/eurheartj/suaa118 |
_version_ | 1783590736487251968 |
---|---|
author | Ferrari, Roberto Censi, S Cimaglia, P |
author_facet | Ferrari, Roberto Censi, S Cimaglia, P |
author_sort | Ferrari, Roberto |
collection | PubMed |
description | In subjects with cardiovascular risk factors or in patients in need of secondary prevention, hypertriglyceridemia is a well-defined risk factor for adverse cardiac events. Drugs containing n-3 polyunsaturated fatty acids (n-3 PUFAs) are approved for treatment of hypertriglyceridemia. In 1999, a cardioprotective effect in post infarct patients was suggested by a large multicentre study, the GISSI prevention trial. The hypothesized mechanism of action was an antiarrhythmic action leading to reduction of the sudden death. However, such a cardioprotective effect of n-3 PUFAs has not been straightforward like for other cardiovascular drugs such as aspirin, statins or ACE inhibitors. On the contrary, it has been a long journey with several ups and downs. Recently, the European Medicines Agency (EMA) has not confirmed the risk benefit of low dose of n-3 PUFA in preventing outcomes after a myocardial infarction. Since the EMA decision, the use of a high dose (4g daily) of pure and stable EPA in a multicentre, international trial, the REDUCE-IT study showed a clear cardiovascular event reduction which was not confirmed in another trial, the STRENGTH study, which utilized 4g daily of an EPA+DHA mixture. It follows that the OMEGA-3 fatty acid story seems to be endless and the last word on cardiovascular benefits cannot be pronounced. We report a brief narrative of an entire journey from the beginning to nowadays. |
format | Online Article Text |
id | pubmed-7537797 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-75377972020-10-13 The journey of omega-3 fatty acids in cardiovascular medicine Ferrari, Roberto Censi, S Cimaglia, P Eur Heart J Suppl Articles In subjects with cardiovascular risk factors or in patients in need of secondary prevention, hypertriglyceridemia is a well-defined risk factor for adverse cardiac events. Drugs containing n-3 polyunsaturated fatty acids (n-3 PUFAs) are approved for treatment of hypertriglyceridemia. In 1999, a cardioprotective effect in post infarct patients was suggested by a large multicentre study, the GISSI prevention trial. The hypothesized mechanism of action was an antiarrhythmic action leading to reduction of the sudden death. However, such a cardioprotective effect of n-3 PUFAs has not been straightforward like for other cardiovascular drugs such as aspirin, statins or ACE inhibitors. On the contrary, it has been a long journey with several ups and downs. Recently, the European Medicines Agency (EMA) has not confirmed the risk benefit of low dose of n-3 PUFA in preventing outcomes after a myocardial infarction. Since the EMA decision, the use of a high dose (4g daily) of pure and stable EPA in a multicentre, international trial, the REDUCE-IT study showed a clear cardiovascular event reduction which was not confirmed in another trial, the STRENGTH study, which utilized 4g daily of an EPA+DHA mixture. It follows that the OMEGA-3 fatty acid story seems to be endless and the last word on cardiovascular benefits cannot be pronounced. We report a brief narrative of an entire journey from the beginning to nowadays. Oxford University Press 2020-10-06 /pmc/articles/PMC7537797/ /pubmed/33061867 http://dx.doi.org/10.1093/eurheartj/suaa118 Text en Published on behalf of the European Society of Cardiology. © The Author(s) 2020. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Articles Ferrari, Roberto Censi, S Cimaglia, P The journey of omega-3 fatty acids in cardiovascular medicine |
title | The journey of omega-3 fatty acids in cardiovascular medicine |
title_full | The journey of omega-3 fatty acids in cardiovascular medicine |
title_fullStr | The journey of omega-3 fatty acids in cardiovascular medicine |
title_full_unstemmed | The journey of omega-3 fatty acids in cardiovascular medicine |
title_short | The journey of omega-3 fatty acids in cardiovascular medicine |
title_sort | journey of omega-3 fatty acids in cardiovascular medicine |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7537797/ https://www.ncbi.nlm.nih.gov/pubmed/33061867 http://dx.doi.org/10.1093/eurheartj/suaa118 |
work_keys_str_mv | AT ferrariroberto thejourneyofomega3fattyacidsincardiovascularmedicine AT censis thejourneyofomega3fattyacidsincardiovascularmedicine AT cimagliap thejourneyofomega3fattyacidsincardiovascularmedicine AT ferrariroberto journeyofomega3fattyacidsincardiovascularmedicine AT censis journeyofomega3fattyacidsincardiovascularmedicine AT cimagliap journeyofomega3fattyacidsincardiovascularmedicine |